Teriparatide, abaloparatide, and amylin lead 26 spaceflight-relevant peptides for on-demand in-situ production feasibility
Background
Long-duration crewed space missions face significant challenges in maintaining pharmaceutical supply chains due to radiation-induced drug degradation, storage constraints, and the impracticality of transporting temperature-sensitive biologics. Current Earth-dependent models are unsustainable for multi-year expeditions beyond Earth orbit. Peptide therapeutics, with their high target specificity, structural programmability, and favorable safety profiles, represent a promising class for in-situ manufacturing. Developing self-sufficient medical capabilities is crucial to address potential health risks and ensure crew safety during deep space exploration.
Study Design
This study evaluated the operational and clinical relevance (OCR) and recombinant production feasibility (RPF) of 26 peptide-based medications relevant to spaceflight. Researchers built upon established astropharmacy databases and literature to identify these candidates. Each peptide was ranked using ten predefined OCR and RPF criteria, including regulatory status, shelf stability, storage requirements, NASA Human Research Roadmap risk/impact score, purification needs, amino acid chain length, prior recombinant production, functional assay availability, dosing requirements, and post-translational modification complexity. All criteria were scored from 0-2 points to determine overall suitability.
Results
The comprehensive evaluation identified several peptide therapeutics as highly suitable for on-demand in-situ production. Teriparatide achieved the highest overall score, reaching 17/20 points, indicating its strong potential. Abaloparatide and amylin closely followed, both scoring 16/20 points.
Several other therapeutics, including angiotensin II, daptomycin,
GLP-1agonists,G-CSF,GM-CSF, and salmon calcitonin, also demonstrated significant promise, each scoring 14/20 points. These high scores reflect a favorable balance of clinical utility in spaceflight scenarios and the practical feasibility of their recombinant production and purification in resource-limited environments, providing a robust framework for future astropharmacy development.
Key Findings
- Teriparatide scored highest at 17/20 points for on-demand space production feasibility.
- Abaloparatide and amylin were strong contenders, each scoring 16/20 points.
- Angiotensin II, daptomycin,
GLP-1agonists,G-CSF,GM-CSF, and salmon calcitonin all scored 14/20 points. - A total of 26 peptide-based medications were evaluated using ten predefined criteria.
- The study provides a structured framework for guiding future astropharmacy development.
Why It Matters
This analysis provides a critical framework for developing self-sufficient medical capabilities for deep space missions, fundamentally shifting away from Earth-dependent pharmaceutical supply chains. The identification of specific peptides like teriparatide, abaloparatide, and amylin as prime candidates offers a clear roadmap for future research and development in astropharmacy. For biohackers and researchers, this highlights the potential for novel, on-demand peptide synthesis technologies that could be adapted for terrestrial applications, particularly in remote or austere environments. This work doesn't change current protocols but rather informs the strategic selection of peptides for future in-space manufacturing, potentially enabling more robust and resilient medical support for astronauts.
spaceflight
peptide-therapeutics
teriparatide
abaloparatide
amylin
astropharmacy